Kathe Stauber, Ph.D. Director of DMPK
Dr Stauber joined DNS as Director of Drug Metabolism and Pharmacokinetics in 2014 and is responsible for both drug discovery and drug development activities. She has 20 yr experience in the pharmaceutical industry conducting nonclinical research at Achillion Pharmaceuticals, Johnson & Johnson, Schering-Plough and Wyeth-Ayerst. Prior to joining DNS, Dr. Stauber managed nonclinical drug development for seven years at Achillion Pharmaceuticals leading to 5-clinical stage compounds. Dr Stauber holds a Ph.D. in Toxicology from Rutgers University and a B.S. from Cook College.